Regeneron Pharmaceuticals Dividends and Buybacks
Dividend criteria checks 0/6
Regeneron Pharmaceuticals is a dividend paying company with a current yield of 0.45%.
Key information
0.5%
Dividend yield
4.7%
Buyback Yield
| Total Shareholder Yield | 5.2% |
| Future Dividend Yield | 0.5% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | 6% |
Recent dividend and buyback updates
Recent updates
Regeneron: The Turnaround Is Gaining Steam
Dec 20Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Nov 19
Regeneron Pharmaceuticals' (NASDAQ:REGN) Anemic Earnings Might Be Worse Than You Think
Nov 09Regeneron: Still A Biotech Juggernaut
Apr 16Dupixent And EYLEA Will Open New Therapeutic Frontiers
Promising pipeline and Dupixent’s market expansion are expected to drive revenue growth and improve net margins.Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow
Apr 06Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Mar 14Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025
Feb 04Regeneron: Phase III Success In Skin Cancer For Libtayo
Jan 15Regeneron's Diversified Growth Makes It My Top Biopharma Pick For 2025
Jan 05Regeneron: Recent Bear Run May Be Justified -- Pharma Faces A Testing 2025
Dec 06Regeneron: The Biotech Stock To Buy Now
Nov 19Stability and Growth of Payments
Fetching dividends data
Stable Dividend: REGN is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: REGN is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Dividend Yield vs Market
| Regeneron Pharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (REGN) | 0.5% |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.4% |
| Industry Average (Biotechs) | 2.4% |
| Analyst forecast (REGN) (up to 3 years) | 0.5% |
Notable Dividend: REGN's dividend (0.45%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.43%).
High Dividend: REGN's dividend (0.45%) is low compared to the top 25% of dividend payers in the US market (4.39%).
Earnings Payout to Shareholders
Earnings Coverage: REGN is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash Flow Coverage: REGN is not paying a notable dividend for the US market.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/04 16:56 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Regeneron Pharmaceuticals, Inc. is covered by 61 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Skorney | Baird |
| James Birchenough | Barclays |